...
首页> 外文期刊>Journal of Molecular Liquids >Gelation behavior, drug solubilization capacity and release kinetics of poloxamer 407 aqueous solutions: The combined effect of copolymer, cosolvent and hydrophobic drug
【24h】

Gelation behavior, drug solubilization capacity and release kinetics of poloxamer 407 aqueous solutions: The combined effect of copolymer, cosolvent and hydrophobic drug

机译:凝胶化行为,药物溶解能力和脱氧剂407水溶液的释放动力学:共聚物,共聚物和疏水性药物的综合作用

获取原文
获取原文并翻译 | 示例
           

摘要

The study elucidated the combined effect of the formulation parameters (the relative contents of the copolymer (poloxamer 407 (P407)), the cosolvent (isopropyl alcohol), and the hydrophobic drug (ibuprofen)) on gelation, applicative properties, drug solubilization capacity and release kinetics of the P407 aqueous solutions under the common conditions of storage and topical administration. The presence of ibuprofen at a therapeutic concentration of 5% enhanced the increase in micellar volume fraction and allowed the gelation of the liquid solutions at P407 concentrations >= 15%. Light microscopy, DSC analysis, and theological measurements pointed that P407 gels with 15-20% of the copolymer enabled controled precipitation of amorphous ibuprofen particles (<= 100 mu m) in perimicellar microchannels, while gels with 25-30% of P407 as well as increased relative content of the cosolvent in perimicellar aqueous phase, had capacity for complete ibuprofen solubilization. The dissolution of the drug partides during the in vitro drug release test, maintained the drug concentration gradient between the perimicellar microchannels and the acceptor medium allowing diffusion-based sustained drug release up to 12 h. The gels with completely solubilized drug notably decrease drug release rate and the cumulative amount of the drug released. Harmonization of the investigated formulation parameters was critical to the formulation of P407 gels that could be promising drug delivery systems for sustained percutaneous delivery of the hydrophobic model drug ibuprofen with reduced frequency of administration and improved patient compliance. (C) 2020 Elsevier B.V. All rights reserved.
机译:该研究阐明了制剂参数(共聚物的相对含量(泊洛沙姆407(P407)),脱溶剂(异丙醇)和疏水药物(布洛芬))的综合作用对凝胶化,应用性质,药物溶解能力和疏水药物(布洛芬))。在储存和局部施用的常见条件下释放P407水溶液的动力学。在治疗浓度为5%的布洛芬的存在增强了胶束体积分数的增加,并允许在P407浓度> = 15%时凝胶化液体溶液。光学显微镜,DSC分析和神学测量指出,具有15-20%的共聚物的P407凝胶使得在PerimicleLar微通道中的无定形布洛芬颗粒(<=100μm)沉淀,而P407的25-30%的凝胶也是如此随着围菌水相中的共溶剂的相对含量增加,具有完全布洛芬溶解的能力。药物偏的溶解在体外药物释放试验期间,将允许扩散的持续药物释放到12小时之间的围绕围绕微型通道和受体培养基之间的药物浓度梯度。具有完全溶解的药物的凝胶显着降低药物释放速率和释放药物的累积量。调查的制剂参数的协调对于P407凝胶的制剂至关重要,该P407凝胶可能是用于持续经皮的药物递送系统,其持续经皮模型药物布洛芬的持续递送,并降低给药频率和改善的患者依从性。 (c)2020 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号